Sygnature Discovery, a leading drug discovery and pre-clinical services company, have appointed Dr Nick Moore as Senior Director, Business Development, in a newly-created role to promote the in vivo pharmacology and consultancy services offered by RenaSci, a wholly-owned subsidiary company.
Dr Moore is an internationally recognised drug discovery and development specialist who has spent nearly 40 years working in the field of in vivo pharmacology. Previous roles include research appointments at Eli Lilly, Lundbeck Research USA, and Albany Molecular Research Inc. (AMRI), and business development positions at Brains On-Line and Charles River Laboratories. He earned his PhD in neuropharmacology from the University of Birmingham and career highlights include a key involvement in the development of Lilly’s anti-psychotic drug Zyprexa (olanzapine).
One of Dr Moore’s key tasks will be to ensure that the synergistic in vitro and in vivo services and drug discovery expertise offered by Sygnature Discovery and RenaSci are maximised for the benefit of clients. “I plan to focus on growing the in vivo pharmacology business and ensure that both current and new customers are aware of the expanded service-offering that the wider Sygnature Group is now able to provide”, Dr Moore said.
“Nick is a very experienced drug discovery scientist who brings a huge amount of in vivo pharmacology know-how and proficiency into the business," said Dr Paul Clewlow, Sygnature Discovery’s Senior Vice President, Business Development and a member of the Board at Sygnature and RenaSci. “I am pleased that Nick has joined my team as he will work closely with colleagues at RenaSci and Sygnature to convey the enhanced capabilities and expertise we offer to clients and identify new in vivo pharmacology capabilities that will complement and augment our current integrated offering.”
RenaSci, founded in 2001, became part of the Sygnature Group in July 2018 following several successful project collaborations with joint clients. Sygnature and RenaSci were amongst the first companies to be established at BioCity Nottingham, the R&D site where Boots Pharmaceuticals discovered ibuprofen. The strategic acquisition of RenaSci by Sygnature stemmed from a long-standing mutual respect between the organisations and the firm belief by Sygnature that combining the two companies would be beneficial not only to their customers, but ultimately to patients with considerable unmet medical need in abuse and dependence, CNS disorders, obesity, diabetes, NASH and kidney disease.
“We realised that RenaSci and Sygnature Discovery were highly-complementary businesses because we have a strong shared focus on high-quality science and delivering new and efficacious drugs to patients,” said Dr Sharon Cheetham, Assistant Professor and Executive Director at RenaSci. “I am delighted to welcome Nick to the Group and we look forward to working with him to expand our business and better serve our clients in the drug discovery and pre-clinical sector."
"Nick is a very experienced drug discovery scientist who brings a huge amount of in vivo pharmacology know-how and proficiency into the business."
Dr Paul Clewlow, Senior VP Business Development
DISCLAIMER: The statements, opinions, views and advice expressed in this article are those of the author/organisation and not of ENTIRELY. This article should represent information correct at the time of publication however whilst every care has been taken to present up-to-date and accurate information, we cannot guarantee that inaccuracies will not occur. ENTIRELY will not be held responsible for any claim, loss, damage or inconvenience caused as a result of any information within this article or any information accessed through this site. The content of any organisations websites which you link to from ENTIRELY are entirely out of the control of ENTIRELY, and you proceed at your own risk. These links are provided purely for your convenience and do not imply any endorsement of or association with any products, services, content, information or materials offered by or accessible to you at the organisations site.